Introduction
============

It is estimated that COPD afflicts from 4% to 10% of adults and is the fourth leading cause of death worldwide ([@b60-copd-2-95]; [@b74-copd-2-95]; [@b44-copd-2-95]; [@b33-copd-2-95]). The true global burden of COPD may be even greater as the condition is often under-diagnosed ([@b33-copd-2-95]). Cigarette smoking is the primary cause of COPD, but environmental and genetic factors also contribute to the disease burden. The primary objective of COPD management is disease prevention through promoting smoking cessation and improving air quality. Other important goals of COPD management include efforts to slow progression of the disease, improve symptoms and overall health status, treat and prevent exacerbations, and reduce mortality.

Inhaled bronchodilators play an important role for improving chronic symptoms and management of exacerbations in COPD, but they have not been shown to reduce mortality or slow the accelerated decline in lung function over time that typifies this disease. The two major classes of inhaled bronchodilators commonly used for COPD are beta adrenergic agonists and anticholinergics. In recent years longer-acting bronchodilators of both drug classes have been widely introduced into clinical practice, either complementing or replacing shorter-acting drugs. This article focuses on tiotropium (Spiriva^®^, Boehringer Ingelheim), a newly developed, long-acting, potent anticholinergic agent that was approved for use in Europe in 2002 and in the United States and Canada in 2004. We will review what has been learned about the clinical benefits and safety of this drug, relying primarily on results from peer reviewed multi-dose, randomized, controlled trials.

Mechanism of action
===================

Atropine, as well as the short-acting inhaled bronchodilator ipratropium, and the long-acting inhaled bronchodilator tiotropium, are muscarinic receptor antagonists. Unlike atropine, tiotropium and ipratropium (Atrovent^®^, Boehringer Ingelheim) are quaternary ammonium cation compounds that are poorly absorbed across cell membranes, thus limiting their effects mainly to the airways after inhalation. Three types of muscarinic receptors have been identified in human airways. Two of these receptors, M~1~ located in parasympathetic ganglia, and M~3~ located on airway smooth muscle, mediate bronchoconstriction via the discharge of acetylcholine from vagal nerve endings ([@b14-copd-2-95]). M~2~ receptors are located on postganglionic cholinergic nerve endings and on smooth muscle and provide negative feedback so as to counteract smooth muscle contraction. Thus, antagonism of the M~1~ and M~3~ receptors reduce smooth muscle tone and cause beneficial bronchodilation while inhibition of the M~2~ receptor has the opposite effect. Ipratropium and atropine nonselectively block all three receptors, but tiotropium is more selective for the M~1~ and M~3~ receptors, from which it dissociates much more slowly ([@b9-copd-2-95]). Consequently, tiotropium is a somewhat more potent bronchodilator than is ipratropium, and has a much longer duration of action. A single dose of inhaled tiotropium produces bronchodilation that is sustained for 24 hours or more ([@b9-copd-2-95]).

Cholinergic-mediated pathways also modulate mucus production, vascular tone, and possibly a variety of immune pathways in the airways, raising the question as to whether any of the clinical benefits of anticholinergic therapy in COPD might be mediated via mechanisms other than bronchodilation ([@b38-copd-2-95]; [@b49-copd-2-95]; [@b14-copd-2-95]). The evidence for this is inconclusive. Excess mucus production is thought to be clinically important in COPD. However, efforts to show that inhaled anticholinergics reduce the volume of sputum production in patients with obstructive lung disease have yielded mixed results ([@b40-copd-2-95]; [@b62-copd-2-95]).

Characteristics of study populations
====================================

All tiotropium trials conducted to date enrolled relatively homogeneous populations of COPD patients (Table [1](#t1-copd-2-95){ref-type="table"}). Most patients had moderate to severe disease by spirometric criteria (forced expiratory volume in one second/forced vital capacity \[FEV~1~/FVC\] \< 0.70 and FEV~1~ \< 65% of predicted) ([@b46-copd-2-95]). Patients with predominant asthma were excluded by clinical criteria. The majority of participants were men, and the average age of patients in most trials was typically in a range of 60--70 years. All trials banned concomitant use of ipratropium, and most prohibited the use of long-acting beta agonists, but inhaled corticosteroids and unlimited albuterol rescue therapy were generally permitted. Most trials also excluded patients with unstable heart disease, severe or inadequately treated urinary outflow obstruction, narrow angle glaucoma, or moderate to severe azotemia.

Delivery of tiotropium in all studies was by inhalation via a single-dose dry powder delivery device (Handihaler^®^, Boehringer Ingelheim) ([@b27-copd-2-95]). The dose of tiotropium was 18 μg/day, as dose-ranging studies indicated that higher doses increase the incidence of adverse effects without providing significant additional improvement in pulmonary function ([@b39-copd-2-95]). Tiotropium was usually given in the morning, although the time of administration has little effect on lung function over a 24-hour period ([@b19-copd-2-95]).

Effects on lung function and exercise
=====================================

Spirometry
----------

Treatment-related bronchodilator effects, as assessed by spirometry, were evaluated in all tiotropium trials. Spirometry is a useful surrogate for clinical outcomes because airflow limitation is a defining feature of COPD and because spirometric variables such as the FEV~1~ correlate with the severity of respiratory symptoms, with exercise capacity, and with mortality, albeit in an imperfect fashion ([@b7-copd-2-95]). The FEV~1~ is easily measured, and because it is more reproducible than most other efficacy outcomes in COPD, statistically significant changes can be detected with relatively modest sample sizes. Trough FEV~1~, measured in the morning 23--24 hours after the last dose of study drug, was the primary outcome in a number of tiotropium studies. Other spirometric assessments included FVC, peak and area under the curve for both FEV~1~ and FVC, and inspiratory capacity (IC). The direction and relative magnitude of the changes seen with these measurements were generally similar to those observed with trough FEV~1~.

Several short-term (4--12 weeks) studies demonstrated that tiotropium increases mean peak FEV~1~ by between 210 mL and 265 mL and mean trough FEV~1~ by between 120 mL and 184 mL ([@b26-copd-2-95]; [@b50-copd-2-95]; [@b28-copd-2-95]; [@b70-copd-2-95]). In a larger 12-week study, Beeh and associates showed that tiotropium increased mean trough FEV~1~ by an average of 79 mL, compared with placebo ([@b12-copd-2-95]). They found larger improvements in average trough FEV~1~ (113 mL) in the subgroup of patients with milder COPD (FEV~1~ 50%--70% predicted) compared with the group as a whole. In one trial, mean steady state trough FEV~1~ occurred within 48 hours of treatment initiation, but mean FVC (trough and peak) continued to increase over the first week of continuous treatment ([@b69-copd-2-95]).

Longer-term studies demonstrated similar sustained improvements in lung function with tiotropium. At the end of one 13-week study in patients with severe COPD (mean baseline FEV~1~ 38% predicted), treatment with tiotropium increased peak FEV~1~ by an average of 220 mL and trough FEV~1~ by an average of 150 mL compared with placebo ([@b21-copd-2-95]). In a 1-year study of 921 patients with severe COPD (mean baseline FEV~1~ 38%--39% predicted), treatment with tiotropium, compared with placebo, improved mean trough FEV~1~ by between 120 and 150 mL on the various assessment days ([@b23-copd-2-95]). Similar results were reported in other 6-month and 12-month studies ([@b17-copd-2-95]; [@b48-copd-2-95]). The MISTRAL study, performed in patients with somewhat milder COPD (mean FEV~1~ 48% predicted), showed similar effects from tiotropium on both peak and trough FEV~1~ ([@b31-copd-2-95]). Rodrigo and associates calculated that tiotropium, compared with placebo, conferred weighted mean improvements of 120 mL in the trough FEV~1~ and 210 mL in the peak FEV~1~ among 4214 patients entered in eight trials ([@b57-copd-2-95]).

Overall, the correlation of FEV~1~ changes with clinically relevant outcomes, such as dyspnea and health-related quality of life (HRQL), is relatively weak in COPD patients and no general consensus exists as to what constitutes a clinically meaningful improvement. Anchoring of FEV~1~ changes to clinical outcomes, such as dyspnea and exacerbation, suggests that increases on the order of 100 mL are clinically noticeable in certain settings ([@b55-copd-2-95]; [@b47-copd-2-95]; [@b29-copd-2-95]). Thus, it is expected that the bronchodilator effects with tiotropium should be sufficiently large to provide some meaningful impact on clinical outcomes.

Acute bronchodilator responses as predictors of long-term tiotropium responses
------------------------------------------------------------------------------

Although asthma patients were excluded by clinical criteria in all of the tiotropium trials, none were excluded because the acute bronchodilator response exceeded some arbitrary upper limit. Consequently, individual bronchodilator responses to a short-acting bronchodilator varied over a fairly wide range in those studies where that information is provided ([@b24-copd-2-95], [@b25-copd-2-95]; [@b12-copd-2-95]; [@b68-copd-2-95]). None of the aforementioned studies reported whether initial responses to short-acting bronchodilators predicted long-term bronchodilator responses to tiotropium. In a secondary analysis of two 1-year trials, patients who had larger responses (≥12% increase and ≥ 200 mL in FEV~1~) to tiotropium on study day 1 were compared with patients with poorer responses to tiotropium ([@b64-copd-2-95]). Responsive patients, compared with less responsiveness patients, exhibited greater improvement in mean trough FEV~1~ at the end of the 1-year follow-up (212 ± 17 mL vs 94 ± 17 mL, respectively), but differences in various clinical outcomes tended to be small and mostly statistically insignificant. Neither the initial response to a short-acting bronchodilator nor the initial response to tiotropium has been shown to provide useful information about long-term clinical outcomes with tiotropium. This is consistent with other evidence demonstrating the futility of using acute bronchodilator responses as a guide to therapy in COPD ([@b19-copd-2-95]).

Disease modification -- FEV~1~ decline over time
------------------------------------------------

Accelerated age-related decreases in the FEV~1~ typify the natural history of COPD. Though the FEV~1~ is a surrogate out-come, it is widely accepted that slowing the decline in FEV~1~ over time can be viewed as "disease modifying", as there is the expectation of eventual reductions in morbidity and mortality. To date, smoking cessation is the only intervention that is known to slow the annual rate of decline in FEV~1~ in patients with COPD ([@b4-copd-2-95]). Pharmacologic interventions have been mostly unsuccessful. Several large randomized trials failed to show a statistically significant effect of high dose inhaled corticosteroids on FEV~1~ decline over 3 years in patients with mild to moderate COPD, though summary estimates do not exclude a small effect ([@b34-copd-2-95]; [@b61-copd-2-95]). Similarly, the Lung Health Study found that regular treatment with ipratropium over a 5-year period had no effect on the rate of decline in FEV~1~ in patients with mild COPD ([@b5-copd-2-95]).

Preliminary evidence suggests that treatment with tiotropium might alter the progression of COPD. A post-hoc analysis of data from a previously published study ([@b23-copd-2-95]) found that treatment with tiotropium between study days 8 and 344 statistically significantly reduced the mean rate of decline in trough FEV~1~ by 46 mL/year compared with placebo ([@b8-copd-2-95]). In a systematic review, Barr and colleagues confirmed that result and also reported a similar effect from tiotropium when it was compared with ipratropium ([@b10-copd-2-95]; [@b71-copd-2-95]). A mean effect size of 46 mL/year is substantially larger than that reported in the ICS trials (5--8 mL/year) and would be viewed as clinically meaningful, if confirmed. These preliminary results formed the basis of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial. The study has completed enrollment of 6000 patients with COPD and the primary objective is to determine whether tiotropium slows the decline in lung function (as measured by FEV~1~) over a 4-year period ([@b15-copd-2-95]). Results of the study are expected in 2008.

Dynamic hyperinflation and exercise performance
-----------------------------------------------

Along with airflow limitation, hyperinflation is thought to play an important role in the genesis of exertional dyspnea, the symptom that is so characteristic of more advanced COPD ([@b18-copd-2-95]). In contrast to normal subjects, end-expiratory lung volume (EELV) increases during exercise in patients with severe COPD. Hyperinflation can be assessed indirectly without resorting to plethysmography by measuring the reduction in IC ([@b51-copd-2-95]). Hyperinflation is essential for maintaining the higher expiratory flow and minute ventilation rates that allow the COPD patient to meet the increased metabolic demands of exercise ([@b18-copd-2-95]). However, dynamic lung hyperinflation also carries a penalty because the respiratory system becomes progressively less compliant at larger lung volumes. It is thought that the resultant increase in the elastic component of respiratory muscle work has an important bearing on the sensation of breathlessness.

[@b50-copd-2-95] compared tiotropium with placebo for 6 weeks and found that tiotropium increased resting and end-exercise IC and VC, decreased resting residual volume and functional residual volume, and improved mean exercise endurance time by an average of 105 sec (21%). In a 4-week study [@b26-copd-2-95] showed that treatment with tiotropium, compared with placebo, improved resting trough IC (by an average of 220 mL), and reduced trough thoracic gas volume (by an average of 540 mL). Similar effects on lung hyperinflation and exercise have been reported in other trials (Maltais et al 2005; [@b12-copd-2-95]; [@b70-copd-2-95]).

Studies of dynamic hyperinflation during exercise provide interesting new insights into the mechanism of dyspnea relief from bronchodilators in COPD patients. It has been suggested that bronchodilator-induced increases in IC and EELV may be better predictors of improvement in exertional dyspnea and exercise times than changes in FEV~1~, though this claim has not been fully substantiated ([@b13-copd-2-95]; [@b51-copd-2-95]). IC measurements are substantially less reproducible than more conventional measurements, such as the FEV~1~ ([@b3-copd-2-95]), and their capability for distinguishing small bronchodilator effects is correspondingly weaker. It also bears emphasizing that the capability for reducing dynamic hyperinflation, though best studied with tiotropium, is most likely a generic effect common to all bronchodilators ([@b13-copd-2-95]).

Tiotropium may also provide a useful adjunct to pulmonary rehabilitation. [@b22-copd-2-95] demonstrated that tiotropium amplified the benefits of endurance training in patients with severe COPD (FEV~1~ 35% predicted). Over an 8-week program, patients receiving tiotropium improved their mean constant work rate endurance time by 80% as compared with only 57% in patients receiving placebo. This difference was well maintained over a subsequent 12-week period when all patients continued study drug but received no further formal endurance training.

Arterial blood gases and sleep-related oxygen desaturation
----------------------------------------------------------

The effect of tiotropium on resting awake arterial blood gases has not been well studied, although tiotropium does improve sleep-related oxygen desaturation (S~a~O~2~) in patients with COPD. After 1 month of treatment with tiotropium, administered once a day in the evening, mean S~a~O~2~ during REM was modestly (3.1%) but statistically greater than placebo, with a similar trend for patients who took tiotropium in the morning ([@b43-copd-2-95]). The improvement in S~a~O~2~ was most strongly correlated with increases in end-of-treatment FEV~1~. Tiotropium had no effect on the S~a~O~2~ while subjects were awake, the amount of time they spent in REM, or self-reports of sleep quality or daytime sleepiness.

Patient-centered outcomes
=========================

Direct measurement of patient-centered outcomes, such as health related quality of life, respiratory symptoms, exacerbations, mortality, adverse drug events, and costs, are increasingly recognized as the most important components in COPD trials ([@b63-copd-2-95]). Tiotropium has been shown to improve many of these outcomes.

Health-related quality of life (HRQL)
-------------------------------------

The St. Georges Respiratory Questionnaire (SGRQ) is the most widely used and arguably the best validated instrument for assessing health status in COPD patients. An improvement of at least 4 points in the SGRQ score is judged to be the clinically meaningful difference ([@b36-copd-2-95]). In a summary analysis of 3 controlled trials, [@b11-copd-2-95] reported that tiotropium, compared with placebo, improved total SGRQ score by a weighted mean difference of −3.3 units (95% CI, −5.6 to −1.0). While the mean change fell short of the 4-unit change that is considered clinically noticeable, treatment with tiotropium, compared with placebo, did significantly increase the likelihood that an individual patient would achieve an improvement of 4 units or more (odds ratio, 1.9; 95% CI, 1.4--2.7).

Dyspnea
-------

Dyspnea plays a central role in the disability of patients with advanced COPD ([@b56-copd-2-95]). Dyspnea evaluation is a component of the SGRQ, but the Transitional Dyspnea Index (TDI) provides a more specific assessment of functional impairment due to breathlessness ([@b41-copd-2-95]). The clinically meaningful difference for the TDI score has been reported to be a 1 unit change ([@b73-copd-2-95]). Compared with placebo, tiotropium affected statistically significant mean improvements of 1.1 units in a 6-month trial and 0.8--1.1 units at various time points in a 1-year trial ([@b23-copd-2-95]; [@b17-copd-2-95]).

Exacerbations
-------------

Results from multiple trials consistently show that tiotropium, compared with placebo, reduces the frequency and severity of COPD exacerbations ([@b23-copd-2-95]; [@b17-copd-2-95]; [@b48-copd-2-95]; Verkindre et al 2005; [@b12-copd-2-95]; [@b31-copd-2-95]). Most trials were not clearly designed with exacerbation as the primary outcome and much of the information about exacerbations was collected through adverse event reporting. The single trial that was designed specifically to evaluate exacerbation frequency was also the largest of the trials and it fully confirmed the results obtained in other studies ([@b48-copd-2-95]). Though there was some variation from trial to trial, most used an "event-based" definition of exacerbation that required the occurrence of typical symptom complexes coupled with some form of medical intervention, such as antibiotic or systemic corticosteroid use.

Several meta-analyses summarized the results from available trials ([@b59-copd-2-95]; [@b72-copd-2-95]; [@b10-copd-2-95], [@b11-copd-2-95]; [@b57-copd-2-95]). A recent systematic review included 6 placebo-controlled trials of greater than 12 weeks duration and involving 6301 patients ([@b11-copd-2-95]). The summary odds ratio of having one or more exacerbations for tiotropium, compared with placebo, was 0.74 (95% CI, 0.66--0.83) (Figure [1](#f1-copd-2-95){ref-type="fig"}). No subgroups have been clearly identified to whom treatment is more effective or less effective.

There is also solid evidence that tiotropium reduces the frequency of hospitalizations among those patients who suffer a COPD exacerbation. Hospitalization is very important in human terms, because of its morbidity and increased risk of mortality, and in economic terms because of the inordinately high costs. In the United States, hospital admissions are the single largest source of medical expenditures for COPD, accounting for up to 70% of the total costs of medical care for this disease ([@b35-copd-2-95]).

Information about COPD hospitalization rates were provided in four large placebo-controlled trials ([@b23-copd-2-95]; [@b17-copd-2-95]; [@b48-copd-2-95]; [@b31-copd-2-95]). All studies are consistent in showing fewer hospitalizations among subjects who received tiotropium with the relative reduction in individual trials ranging between 13% and 42%. [@b11-copd-2-95] calculated the summary odds ratio for tiotropium relative to placebo in these 4 trials as being 0.69 (95% CI, 0.55--0.87) (Figure [1](#f1-copd-2-95){ref-type="fig"}).

Since most COPD exacerbations are thought to be caused by infections, the mechanism by which tiotropium reduces the frequency and severity of COPD exacerbations is uncertain. Improvements in lung function and dyspnea could reduce patients' perception of the severity of exacerbations, thereby decreasing the likelihood that they would seek medical attention. That event would not be counted as an exacerbation, as exacerbation has been defined in most of the tiotropium trials. Other possible mechanisms might include more efficient cough and clearance of respiratory secretions due to better bronchodilation, protection against lung injury due to hyperinflation, or specific anticholinergic effects on mucus secretion or bronchial inflammation ([@b48-copd-2-95]; [@b66-copd-2-95]).

Mortality
---------

Salpeter and associates reported that inhaled anticholinergics (tiotropium and ipratropium trials combined), compared with placebo, reduced the risk of *respiratory* deaths (RR 0.27, 95% CI 0.09--0.81) based on a meta-analysis of 5 trials with 7881 participants ([@b58-copd-2-95]). However, the total number of respiratory deaths were few and ascertainment of disease-specific mortality is fraught with uncertainties. In 6 trials involving 4770 patients, Barr and colleagues found that treatment with tiotropium, compared with placebo, did not significantly reduce *all-cause* mortality (OR, 0.91; 95% CI, 0.58--1.42) ([@b11-copd-2-95]) (Figure [1](#f1-copd-2-95){ref-type="fig"}). Because of its large size and long duration, the UPLIFT study should provide more definitive information about the effect of tiotropium on mortality.

Comparisons with active controls
================================

One randomized trial compared tiotropium to inhaled ipratropium (40 μg qid) as an active control over a 1-year period in 535 patients ([@b71-copd-2-95]). Results were closely similar to those trials in which tiotropium was compared with placebo. At the end of 1 year, trough FEV~1~ was significantly increased by a mean of 120 mL in the tiotropium arm, compared with ipratropium. Additionally, tiotropium, compared with ipratropium, improved the average TDI score by nearly 1 unit, improved average total SGRQ score by 3.3 units, and reduced the proportion of patients who experienced one or more exacerbations (35% vs 46%), all differences being statistically significant (p \< 0.05). There was no significant effect on mortality (Figure [1](#f1-copd-2-95){ref-type="fig"}). Dry mouth was the only adverse event that was significantly increased in the tiotropium arm (12% vs 6%).

Two trials, one of 12 weeks' duration and involving 653 patients and the other of 6 months' duration and involving 807 patients, compared tiotropium with inhaled salmeterol (50 μg bid) ([@b17-copd-2-95]; [@b16-copd-2-95]). Summary analyses of these two trials indicate that tiotropium was superior to salmeterol in terms of trough FEV~1~ at the conclusion of the trials (weighted mean difference, 29 ml; 95% CI, 6--51 mL) ([@b11-copd-2-95]). Though trends favored tiotropium in certain other outcomes, SGRQ scores, TDI scores, exacerbation rates, and mortality did not differ statistically between the two treatment arms (Figure [1](#f1-copd-2-95){ref-type="fig"}). As in other trials, there were more reports of dry mouth with tiotropium compared salmeterol.

Combination therapy with long-acting beta agonists
==================================================

International guidelines for COPD treatment recommended long-acting bronchodilators, either a beta agonist or an anticholinergic, for patients with moderately severe COPD or respiratory symptoms that persist despite the administration of short acting bronchodilators ([@b20-copd-2-95]; ATS/ERS 2004; National Clinical Guideline UK 2004; [@b46-copd-2-95]). As with tiotropium, long-acting beta agonists increase the FEV~1~, improve HRQL and dyspnea scores, and reduce exacerbation rates ([@b72-copd-2-95]). The guidelines state no preference of one class of long-acting bronchodilator over the other, nor do they recommend combination treatment with these agents.

There is limited information about the clinical benefits of combining tiotropium with a long-acting beta agonist. Small, single-dose trials demonstrated additive FEV~1~ improvements when tiotropium is combined with either salmeterol or formoterol ([@b24-copd-2-95], [@b25-copd-2-95]). [@b67-copd-2-95] showed in a 6-week study that, compared with baseline, average daytime FEV~1~ improvements over 12 hours with tiotropium alone, formoterol (12 μg) twice daily, and tiotropium plus once-daily formoterol were 127 mL, 86 mL, and 234 mL, respectively. Average 12 hour night-time FEV~1~ improvements were 43 mL, 38 mL, and 86 mL, respectively. In another study of tiotropium alone or in combination with formoterol, the authors found that, compared with baseline, average FEV~1~ improvements over 24 hours with tiotropium alone, tiotropium plus once-daily formoterol, and tiotropium plus twice-daily formoterol were 80 mL, 162 mL, and 198 mL, respectively ([@b68-copd-2-95]). There was also a significant reduction in albuterol rescue medication in the patients receiving both tiotropium and formoterol, but the trial was not powered to show differences for most relevant clinical outcomes. In contrast with the two previous trials, investigators in another study ([@b68-copd-2-95]) found that, after 7 days of treatment, the difference in average FEV~1~ improvement 2 hours after a dose of formoterol was 124 mL greater than with tiotropium; at 12 hours there was no significant difference.

The Canadian Optimal Therapy of COPD trial is a 3-arm study in 449 patients that compared tiotropium alone, tiotropium plus salmeterol, and tiotropium plus salmeterol plus fluticasone for 52 weeks ([@b1-copd-2-95]). Although there was no significant difference in the primary outcome of the proportion of patients with exacerbations that required treatment with systemic steroids or antibiotics, other outcomes including lung function, disease-specific quality of life, hospitalizations for COPD, and all-cause hospitalization favored treatment with tiotropium plus salmeterol plus fluticasone compared with tiotropium plus placebo. There was no significant differences in these outcomes, comparing tiotropium plus salmeterol with tiotropium alone.

Safety and adverse effects
==========================

Tiotropium has a quaternary ammonium structure so that it is poorly absorbed across cell membranes, thus limiting its activity to local bronchodilating effects and minimizing anticholinergic effects due to systemic absorption. Dry mouth is the most commonly reported adverse drug reaction from tiotropium ([@b37-copd-2-95]). Approximately 4%--16% of patients experience this side-effect, although it tends to improve over time and it rarely (\<1%) necessitates discontinuation of the drug ([@b64-copd-2-95]; [@b31-copd-2-95]). In an analysis of pooled studies including 4435 tiotropium patients and 3384 placebo patients with 2159 and 1662 patient years of exposure, respectively, [@b37-copd-2-95] reported the relative risk for dry mouth in tiotropium patients was 3.60 (95% CI, 2.56--5.05).

Only miniscule amounts of tiotropium are absorbed systemically, but as a drug class, anticholinergics have a potential for causing adverse cardiac effects, particularly tachyarrhythmias. One published article reported a small excess number of tachyarrhythmias among patients with mild COPD who received ipratropium for several years ([@b4-copd-2-95]). However, an excess number of serious cardiac side-effects in patients receiving tiotropium has not been reported in any of the published trials. [@b11-copd-2-95] found no significant difference in the incidence of chest pain, myocardial infarction, congestive heart failure, arrhythmias, or atrial fibrillation with tiotropium compared with controls in their meta-analysis. Caution should be taken before applying these results to all patients with COPD, however, as many studies excluded patients with serious cardiac arrhythmias, recent myocardial infarctions, or hospitalizations for congestive heart failure.

Two studies provide more detailed information regarding potential adverse cardiac effects. One study found no evidence of cardiac toxicity after 6 weeks of tiotropium, as measured by 24-hour electrocardiographic (ECG) monitoring ([@b19-copd-2-95]). A 12-week study found no significant differences in heart rate, conduction abnormalities, rhythm, or QTc duration on 24-hour ECG monitoring over a 12-week period in patients receiving tiotropium, compared with placebo ([@b28-copd-2-95]).

Adverse effects of tiotropium on urinary, renal, gastrointestinal, or ocular function appear to be infrequent. A small but statistically significant increase in urinary tract infections with tiotropium was reported by [@b11-copd-2-95] in their meta-analysis, although there was no significant increase in cases of urinary retention. In the analysis by [@b37-copd-2-95] the relative risk of urinary retention was 10.93 (95% CI, 1.26--94.88). Again, these results may not be generalizable to all patients with COPD, however, as patients with symptoms of moderately severe prostatic hypertrophy or bladder neck outlet obstruction were excluded from participation.

Patients with severe renal impairment were also excluded from most studies. An exception was one study in which tiotropium (4.8 μg) was administered intravenously over 15 minutes to patients with levels of renal insufficiency ranging from mild to severe (creatinine clearance of \<30 mL/min) ([@b65-copd-2-95]). Blood levels of tiotropium, which is secreted mainly by the kidney in unchanged form, doubled in patients with severe renal impairment compared with those with normal renal function, but no adverse clinical effects were observed.

A substantial proportion of inhaled tiotropium is ingested and could in theory cause gastrointestinal dysmotility. In their meta-analysis, [@b11-copd-2-95] found no increase in reports of tiotropium-associated constipation. One case of postoperative paralytic ileus attributed to tiotropium has been reported ([@b54-copd-2-95]).

Due to its anticholinergic effects, tiotropium might also worsen the signs and symptoms of narrow-angle glaucoma, if drug were inadvertently deposited in the eye. One such case has been reported after self application directly in the eye, but exacerbation of glaucoma has not been reported when tiotropium is taken by inhalation as directed ([@b52-copd-2-95]). Nonetheless, tiotropium should be used with caution in patients with narrow angle glaucoma, since they were excluded from all trials.

Cost effectiveness
==================

The cost effectiveness of tiotropium has been formally evaluated based on data from studies performed in Europe and the United States. An economic analysis by [@b53-copd-2-95] performed alongside a clinical trial in the Netherlands ([@b71-copd-2-95]) showed that substituting tiotropium for ipratropium increased mean annual healthcare costs (including acquisition costs for tiotropium) by the equivalent of €180; the additional cost to prevent one COPD exacerbation was €667, and the cost to improve the SGRQ by at least 4 units was €1084. In a retrospective analysis of 2 studies performed in the United States ([@b23-copd-2-95]), [@b32-copd-2-95] found that treatment with tiotropium reduced average total annual healthcare costs by \$US1043 (95% CI, --\$US2136 to \$US48), although this analysis excluded the costs of anticholinergic drug acquisition ([@b32-copd-2-95]). The reduction in healthcare costs with tiotropium in this analysis was entirely due a reduction in the costs of hospitalizations. In a recent systematic review of the pharmacoeconomic evidence of maintenance treatment for COPD, D'Souza et al (2006) concluded that treatment with tiotropium is cost-effective relative to ipratropium. These authors also found that treatment with inhaled corticosteroids is cost effective in patients with moderate-to-severe COPD, but data are lacking regarding the cost-effectiveness of long-acting beta agonists.

Clinical implications
=====================

Tiotropium should be considered for maintenance therapy in patients with moderate to severe COPD. Improvements in pulmonary function with tiotropium are accompanied by improvements in dyspnea, exercise capacity, and HRQL, and a reduction in exacerbations. Although tiotropium has an excellent safety profile in selected patients, the risks and benefits should be carefully weighed in patients with closed angle glaucoma, bladder outlet obstruction or severe cardiac disease. Limited data support the superiority of tiotropium compared with ipratropium; there is insufficient *clinical* evidence to support the choice of tiotropium over long-acting beta agonists. Tiotropium may reduce the economic burden of COPD by reducing the frequency of COPD exacerbations and COPD-related hospitalizations.

![Summary effects of tiotropium on (A) COPD exacerbations, (B) hospitalizations, and (C) all-cause mortality. Reproduced with permission from Barr RG, Bourbeau J, Camargo CA, et al. 2006. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. *Thorax*, 61: 854--62. Copyright © 2006 BMJ Publishing Group Ltd. and the British Thoracic Society.](copd-2-95f1){#f1-copd-2-95}

###### 

Characteristics of trials and their study populations

  **Tiotropium vs Placebo**       **N**   **Duration of trial**   **Age (yr)[a](#tfn1-copd-2-95){ref-type="table-fn"}**   **Gender male/female**                            **FEV~1~[a](#tfn1-copd-2-95){ref-type="table-fn"}(% predicted)**   **FEV~1~/FVC[a](#tfn1-copd-2-95){ref-type="table-fn"}(%)**
  ------------------------------- ------- ----------------------- ------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------
  [@b12-copd-2-95]                1639    12 wk                   62                                                      1237/402                                          45                                                                 57
  [@b19-copd-2-95]                121     6 wk                    66                                                      75/46                                             41                                                                 51
  [@b26-copd-2-95]                81      4 wk                    64                                                      50/31                                             38                                                                 43
  [@b21-copd-2-95]                470     13 wk                   65                                                      307/163                                           39                                                                 46
  [@b23-copd-2-95]                921     12 mo                   65                                                      599/322                                           39                                                                 46
  [@b28-copd-2-95]                196     12 wk                   65                                                      114/82                                            39                                                                 NA
  [@b31-copd-2-95]                1010    12 mo                   65                                                      889/121                                           48                                                                 54
  [@b39-copd-2-95]                169     4 wk                    66                                                      96/73                                             42                                                                 NA
  Maltais 2005                    261     6 wk                    63                                                      189/72                                            43                                                                 44
  [@b43-copd-2-95]                95      4 wk                    66                                                      66/29                                             32                                                                 45
  [@b48-copd-2-95]                1829    6 mo                    68                                                      1802/27                                           36                                                                 48
  [@b50-copd-2-95]                187     6 wk                    60                                                      138/49                                            42                                                                 45
  [@b70-copd-2-95]                100     12 wk                   60                                                      94/6                                              35                                                                 40
  **Tiotropium vs Ipratropium**                                                                                                                                                                                                                
  Van Noord 2000                  288     3 mo                    64                                                      238/47[b](#tfn2-copd-2-95){ref-type="table-fn"}   41                                                                 45
  [@b71-copd-2-95]                535     12 mo                   64                                                      453/82                                            41                                                                 46
  **Tiotropium vs LABA**                                                                                                                                                                                                                       
  Briggs 2003                     653     6 mo                    64                                                      434/397                                           38                                                                 43
  [@b17-copd-2-95]                1207    6 mo                    64                                                      920/287                                           38                                                                 43
  [@b67-copd-2-95]                71      6 wk                    65                                                      56/15                                             37                                                                 38
  [@b68-copd-2-95]                95      2 wk                    64                                                      72/23                                             38                                                                 41

Data are presented as means

\[sic\] M/F numbers do not add up to total subjects in original report

**Abbreviations:** LABA, long-acting beta agonists.

###### 

Effect of tiotropium on spirometry

  **Tiotropium vs Placebo**       **FEV~1~ trough (mL)**                              **FEV~1~ peak (mL)**                                **FVC trough (mL)**                                 **FVC peak (mL)**
  ------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  [@b12-copd-2-95]                79                                                  128                                                 116                                                 176
  [@b19-copd-2-95]                210                                                 \-                                                  320                                                 \-
  [@b26-copd-2-95]                160                                                 220                                                 330                                                 480
  [@b21-copd-2-95]                150                                                 220                                                 280                                                 410
  [@b23-copd-2-95]                120--150[a](#tfn5-copd-2-95){ref-type="table-fn"}   190--220[a](#tfn5-copd-2-95){ref-type="table-fn"}   260--290[a](#tfn5-copd-2-95){ref-type="table-fn"}   420--510[a](#tfn5-copd-2-95){ref-type="table-fn"}
  [@b28-copd-2-95]                184                                                 265                                                 213                                                 388
  [@b31-copd-2-95]                120                                                 \-                                                  170                                                 \-
  [@b39-copd-2-95]                150                                                 \-                                                  370                                                 \-
  Maltais 2005                    150                                                 230                                                 300                                                 410
  [@b48-copd-2-95]                100                                                 170                                                 \-                                                  \-
  [@b50-copd-2-95]                120                                                 220                                                 250                                                 430
  [@b70-copd-2-95]                110                                                 210                                                 80                                                  \-
  **Tiotropium vs Ipratropium**                                                                                                                                                               
  Van Noord 2000                  130                                                 50                                                  210                                                 60
  [@b71-copd-2-95]                150                                                 \-                                                  210                                                 \-
  **Tiotropium vs LABA**                                                                                                                                                                      
  Briggs 2003                     18                                                  46                                                  120                                                 64
  [@b17-copd-2-95]                30                                                  \-                                                  \-                                                  \-
  [@b67-copd-2-95]                41                                                  −3                                                  74                                                  −7

**Notes:** Data are presented as mean change from baseline.

Range of change on different study days.

**Abbreviations:** LABA, long-acting beta agonists.

###### 

Summary of tiotropium effects

  **Benefits**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sustained effects for at least 24 hours from a single doseImproved lung function, exercise capacity, and health-related quality-of-lifeReduced frequency of COPD exacerbation and related hospitalizationsBetter bronchodilation compared with ipratropium or long-acting beta agonistsAdditive bronchodilation when combined with a long-acting beta agonist
  **Adverse effects**
  Dry mouthUrinary retentionSafety in patients with severe cardiac disease, renal failure, untreated bladder outlet obstruction or narrow angle glaucoma is not established
